Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 143.00 151.00 170.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 457

Amryt Pharma Share Discussion Threads

Showing 5351 to 5368 of 7275 messages
Chat Pages: Latest  219  218  217  216  215  214  213  212  211  210  209  208  Older
DateSubjectAuthorDiscuss
14/1/2020
17:41
Some very big sells this afternoon. One for £125k. Yet the quoted spread is unaffected. All rather baffling.
papillon
13/1/2020
17:14
Candid Posts: 285 Price: 126.50 No Opinion chart looking very healthy Fri 11:49 Breakout above 125p, good chance of run-up to previous highs as we approach key catalyst radar Posts: 3,018 Price: 127.50 No Opinion RE: chart looking very healthy Today 13:14 Unlikely >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Well that well known oracle (:-)), radar, has predicted that a rise back up to last Septembers high of 140p, as we approach key AP101 news, is "Unlikely". We shall see. I'll remind radar of his pessimistic prediction if we do "run-up" to last Septembers high pre the AP101 results.
papillon
10/1/2020
08:16
I see they have updated clinical trials and estimated primary completion date has been moved to June.
waterloo01
07/1/2020
19:55
hxxps://www.proactiveinvestors.co.uk/companies/news/903476/amryt-pharma-us-deal-set-to-transform-the-orphan-drug-company-903476.html
digadee
07/1/2020
17:50
Interesting timing, I guess nothing will happen for at least 6 weeks
alphabravo321
07/1/2020
16:34
Little Willy, or Little Wiley? :-)
papillon
07/1/2020
14:54
Little Wiley buy
alphabravo321
19/12/2019
12:02
Good news RNS today on the cash position. "Cash is King"
papillon
19/12/2019
10:24
Management had said that synergies would be $20-40m, so they maybe a top of the range. That would comfortably cover Old Amryt costs. Aegerion in their filing with the bankruptcy court protected net profits after taxes in 2022 of about £70m. If those numbers are in correct ballpark, these shares should go much higher.
sidam
19/12/2019
10:18
From Irish Times today: Amryt Pharma, a Dublin-based biopharmaceutical company, said integration of Aegerion Pharmaceuticals, a company it acquired in September, is “progressing well and ahead of its initial expectations. The company, which focuses on developing treatments to help patients with rare and orphan diseases, noted that its cash position of $60.9 million (€54.7 million), helped by its $57 million fundraising in September, was significantly ahead of expectations at this point. “Amryt has evolved from a company with a single asset on the market in the Europe, the Middle East and Africa (EMEA) to become a global biopharmaceutical company with two orphan disease products and a commercial infrastructure across North America, EMEA and Latin America. Our strategy is to become a global leader in rare and orphan diseases and we are committed to delivering new therapies to patients in areas of high unmet need,” said Amryt chief executive Joe Wiley. He added the company is pleased with the progress being made on the integration of Aegerion, adding that synergies achieved so far have resulted in a higher cash balance at this point than was initially forecast.
panadin
16/12/2019
10:13
mdalos1 - 15 Dec 2019 - 16:52:43 - 5215 of 5216 Amryt Pharma - AMYT No PROMISES made at all then... FAKE News from the usual source No PROMISES clearly committed to in writing in the actual Company literature... more FAKE News from the one & only FLUTTER$H!TE. The only thing clearly communicated about NASDAQ was some possibility of (an unclear/undefined) listing by perhaps late Jan/early Feb (if you use the 90 days most appropriately)... even then there was no PROMISE nor any clear detail. You either understand these things OR you don't and repeatedly lead yourself astray & mislead others. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> You're a C*NT, mdalos. A prize C*NT. I'd love to meet you and tell you you're a C*NT to your face! You're a COWARD who deletes all his posts. In fact this post of yours is the only one you have yet to delete, but no doubt you will delete it very soon. You need a good seeing to, matey. Just as well you are an anonymous poster! That's it for me. No more posts on this bb until we get some news. In fact I wont even read it again until we get some news.
papillon
13/12/2019
19:15
Cathal Friel in this interview, dated 13/9/2019, predicted the NASDAQ listing would take place in November!! LOL. How wrong can you be? Https://www.youtube.com/watch?v=ZqelBgsW39I
papillon
13/12/2019
12:39
mdalos1 13 Dec '19 - 09:03 - 5209 of 5210 (Filtered)
papillon
13/12/2019
09:28
sharesmagazine.co.uk/video/amryt-pharma-amyt-kieran-rooney-vice-president-4
alphabravo321
13/12/2019
00:09
mdalos1 12 Dec '19 - 19:48 - 5207 of 5207 (Filtered)
papillon
12/12/2019
17:09
That's all supposition on your part, gnnmartin. The FACT is AMYT promised the Nasdaq listing would take place within 90 days of the Aegerion deal being finalised and now we know it wont be. There could be any number of different reasons why the Nasdaq listing isn't going ahead and we can all guess why the promise is not being kept, but as we are not AMYT insiders our guesses could be wrong. Unfortunately AMYT will not be telling us why they have failed to keep their promise. The company shouldn't make promises they can't keep!
papillon
12/12/2019
16:30
I assume that Amryt found that their initial investigation of a US listing got discouraging feedback. Perhaps (hopefully) the advice was that listing with AP101 still unresolved would not get a much better price that listing with AP101 written off (as you yourself suggest). In that case they might have decided to wait until the results for AP101 are known, suggesting they are a bit more optimistic than the market.
gnnmartin
12/12/2019
15:16
Who cares when the AP101 phaseIII results are likely to be released? Whether it's March 2020, or March 2021. LOL. Before the Aegerion deal was announced in May 2019 the AMYT share price was drifting downwards and the Mkt Cap implied that investors were NOT confident of AP101 being successful and that very little value was in fact being ascribed to AP101. AMYT is now being valued primarily on the two revenue generating drugs acquired from Aegerion/Novelion and their growth prospects. We have shares in a biotech with projected annual sales of US$150m, a slug of debt (US$220m?) and a Mkt Cap of £164m. Whether that £164m Mkt Cap is fair value for AMYT I have no idea. The share price seems to have settled around the current and there is almost no volume so perhaps investors think it is fair value. The only thing that disappoints me is why there are not any current plans to list on Nasdaq when such a Nasdaq listing was promised when the Aegerion deal was finalised in September. Just goes to show that one should only believe the audited results and ignore what AMYT promises. PS. As far as I'm concerned AMYT have divested AP101 into the CVR's. If AP101 fails phaseIII then the CVR's are worthless. The odds on the CVR's ending up worthless? I've no idea. MADLOSS could be right and there's an 85% chance of failure, or he could be wrong and the odds on success are better than 15%. If AP101 is unsuccessful I wont lose any sleep over it. I've already written them off, so if AP101 is successful I'll have a pleasant surprise. Amicus did a similar thing with their EB treatment acquired from Socioderm. Socioderm shareholders were promised milestone payments totalling over US$600m dependent on a successful phaseIII trial result. In the event the trial results were unsuccessful and the Amicus share price hardly moved. I don't believe the current AMYT Mkt Cap ascribes much, if any, value to AP101. I believe the current AMYT Mkt Cap is almost solely determined by the revenue generated by the 2 drugs acquired by AMYT via Aegerion/Novelion and their growth prospects. Whether the Mkt is fairly valuing AMYT I have no idea.
papillon
Chat Pages: Latest  219  218  217  216  215  214  213  212  211  210  209  208  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220526 16:36:28